Taysha Gene Therapies Inc
TSHAHealthcare|Biotechnology|USA
$6.34
-0.23 (-3.50%)
Tangible Book
$0.74
Upcoming Data Readouts (4)
Mar 2027
Est. completion
P1P2Infantile GM2 Gangliosidosis (Disorder)
First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis
NCT04798235n=3
Nov 2028
Est. completion
P1P2Rett Syndrome
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
NCT06152237n=6
Jun 2031
Est. completion
P3Rett Syndrome
Safety and Preliminary Efficacy of TSHA-102 Gene Therapy in Pediatric Females Aged >2 to <4 Years With Rett Syndrome
NCT07480564n=3
Jun 2031
Est. completion
P3Rett Syndrome
A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
NCT05606614n=17